大连医科大学附属第一医院
  1. 首页
  2. 专家介绍

吴广圳（泌尿）

吴广圳（泌尿）
所属科室：
外科学
职称：
副主任医师
出诊时间：
专家介绍：
医学博士，副主任医师，硕士研究生导师，擅长泌尿系肿瘤、肾上腺及前列腺疾病的诊治，科研主要研究方向基于肾癌脂肪酸代谢机制研究，以第一作者/通讯作者发表SCI论文48篇（第一作者15篇，通讯作者33篇），其中IF>5分SCI文章20篇，累计影响因子（第一/通讯）276.3分，H-score 18分。北京化工大学分子诊断技术创新研究中心特聘专家，iMeta青年编委（2023年预测影响因子15+）, Oxidative medicine and cellular longevity编委（影响因子7.31分），European Journal of medical research杂志副主编（影响因子4.981分），BMC cacner 杂志副主编 （影响因子4.638分），Journal of oncology 学术编委（影响因子4.501分），Oxidative medicine and cellular longevity杂志特刊主编（影响因子6.543分），European Journal of Gynaecological Oncology杂志客座主编，Advances in Urology杂志编委，Journal of oncology肿瘤脂代谢特刊客座编委，现代泌尿外科杂志编委，泌尿外科杂志编委，现代生命科学杂志编委，出版国际版书籍1册，持有发明专利一项（第一发明人），新型实用发明专利二项（第一发明人），主持辽宁省自然基因课题一项，主持辽宁省教育厅课题一项，主持大连市科技之星课题一项，辽宁省医学会泌尿外科分会肿瘤学组委员，大连市“青年科技之星”，大连市“青年才俊”，获得“辽宁省住院医师心中好老师”称号，获得“大连医科大学优秀教师及优秀住培教师”称号，中国抗癌协会肿瘤标志专业委员会、肿瘤生物治疗专业委员会、肿瘤代谢专业委员会及泌尿男生殖系肿瘤专业委员会专业会员，大连医科大学附属第一医院临床流行病与统计学工作室特聘专家，担任Briefings in Bioinformatics，Frontiers in immunology，Journal of urology, Frontiers Cell and Developmental Biology, Journal of translational medicine, All Life, Journal of oncology, Journal of immunology research, Frontiers in medicine, Frontier in oncology, Frontiers in Molecular Biosciences, BMC medical genomics, scientific reports, BMC cancer, Cancer control, Technology in Cancer Research & Treatment，Bioengineered等杂志审稿专家。 在研项目： 1.LXRα调节脂肪酸转运蛋白CPT1A在肾透明细胞癌中的抑瘤作用及机制研究（LZ2020071），507171；立项年度：2020年；立项部门：辽宁省教育厅； 2. CPT2通过调节脂肪酸代谢上调PPARA通路在肾透明细胞癌中的抑瘤作用及机制研究（2021-BS-209），辽宁省自然基金，立项年度：2021年，立项部门：辽宁省科技厅 3. LXR调节肾透明细胞癌胆固醇及脂肪酸平衡机制研究（2021RQ010）；立项年度：2021年；立项部门:大连市科技局。 (1) Xie D, Wang Q, Wu G. Research progress in inducing immunogenic cell death of tumor cells. Front Immunol. 2022 Nov 17;13:1017400. doi: 10.3389/fimmu.2022.1017400. PMID: 36466838; PMCID: PMC9712455. （通讯作者）8.786 (2) Xiaochen Qi, Quanlin Li , Xiangyu Che , Qifei Wang *, Guangzhen Wu* ，Application of regulatory cell death in cancer: Based on targeted therapy and immunotherapy，frontiers in immunology，2022，13:837293.（通讯作者）8.786 Xiangyu Che#, Xiaochen Qi#, Yingkun Xu# , Qifei Wang*, Guangzhen Wu* ，Genomic and transcriptome analysis to identify the role of the mTOR pathway in kidney renal clear cell carcinoma and its potential therapeutic significance，Oxidative Medicine and Cellular Longevity，2021.6613151（通讯作者）7.31 (3) Che X, Qi X, Xu Y, Wang Q, Wu G. Using Genomic and Transcriptome Analyses to Identify the Role of the Oxidative Stress Pathway in Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance. Oxid Med Cell Longev. 2021 Oct 20;2021:5561124. doi: 10.1155/2021/5561124. PMID: 34721758; PMCID: PMC8550864.（通讯作者）7.31 (4) Yan Zhang,#, Mingying Chen#, Meihong Liu, Yingkun Xu *, Guangzhen Wu*, Glycolysis-related genes serve as potential prognostic biomarkers in clear cell renal cell carcinoma, Oxidative Medicine and Cellular Longevity, 2021, 6699808.（通讯作者） 7.31 (5) Wu G, Xu Y, Zhang H, Ruan Z, Zhang P, Wang Z, Gao H, Che X, Xia Q, Chen F. A new prognostic risk model based on autophagy-related genes in kidney renal clear cell carcinoma. Bioengineered. 2021 Dec;12(1):7805-7819. doi: 10.1080/21655979.2021.1976050. PMID: 34636718. （第一作者）6.832 (6) Sun Y, Xu Y, Che X, Wu G. Development of a Novel Sphingolipid Signaling Pathway-Related Risk Assessment Model to Predict Prognosis in Kidney Renal Clear Cell Carcinoma. Front Cell Dev Biol. 2022;10:881490. Published 2022 Jun 29. doi:10.3389/fcell.2022.881490（通讯作者）6.081 (7) Qi X, Che X, Li Q, Wang Q, Wu G. Potential Application of Pyroptosis in Kidney Renal Clear Cell Carcinoma Immunotherapy and Targeted Therapy. Front Pharmacol. 2022 Jun 15;13:918647. doi: 10.3389/fphar.2022.918647. （通讯作者）5.988 (8) Qi X, Wang J, Che X, Li Q, Li X, Wang Q, Wu G. The potential value of cuprotosis (copper-induced cell death) in the therapy of clear cell renal cell carcinoma. Am J Cancer Res. 2022 Aug 15;12(8):3947-3966. PMID: 36119838; PMCID: PMC9442008. （通讯作者）5.942 (9) Sun Y, Xue Z, Huang T, Che X, Wu G. Lipid metabolism in ferroptosis and ferroptosis-based cancer therapy. Front Oncol. 2022 Aug 1;12:941618. doi: 10.3389/fonc.2022.941618. PMID: 35978815; PMCID: PMC9376317.（通讯作者）5.738 (10) Qi X, Li Q, Che X, Wang Q, Wu G. The Uniqueness of Clear Cell Renal Cell Carcinoma: Summary of the Process and Abnormality of Glucose Metabolism and Lipid Metabolism in ccRCC. Front Oncol. 2021 Sep 15;11:727778. doi: 10.3389/fonc.2021.727778. PMID: 34604067; PMCID: PMC8479096.（通讯作者）5.738 邮箱：wuguang0613@hotmail.com